APOE ε4 carriers may present gray matter reductions, decreased resting glucose metabolism in brain regions with potential AD pathology, including the posterior cingulate, parietal, temporal, and prefrontal cortices, and also increased task-related activation in relative regions. This evidence concerns the gene APOE and Alzheimer disease.